599
Views
12
CrossRef citations to date
0
Altmetric
Editorial

Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study

, &
Pages 497-499 | Published online: 10 Jan 2014

References

  • Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis.5, 558–567 (2005).
  • Choo QL, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science244, 359–362 (1989).
  • Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-αlpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med.140, 346–355 (2004).
  • Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet358, 958–965 (2001).
  • Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature461, 399–401 (2009).
  • Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-αlpha and ribavirin therapy. Nat. Genet.41, 1100–1104 (2009).
  • Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure – a genome-wide association study. Gastroenterology138(4), 1338–1345 (2010).
  • Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet.41, 1105–1109 (2009).
  • Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and to spontaneous clearance of hepatitis C virus. Nature461, 798–801 (2009).
  • Kotenko SV, Gallagher G, Baurin VV et al. IFN-λ mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol.4, 69–77 (2003).
  • Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol.4, 63–68 (2003).
  • Li M, Liu X, Zhou Y et al. Interferon-λs: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol.86, 23–32 (2009).
  • Marcello T, Grakoui A, Brba-Spaeth G et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology131, 1887–1898 (2006).
  • Pagliaccetti NE, Eduardo R, Kleinstein SH et al. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J. Biol. Chem.283, 30079–30089 (2008).
  • Shiffnan M, Lawitz E, Zaman A. PEG-IFN-λ: antiviral activity and safety profile in a 4-week Phase 1b study in relapsed genotype 1 hepatitis C infection. J. Hepatol.50, S237 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.